Chuncheon-based Boditech Med exports rapid diagnostic technology to 140 countries
Chuncheon is transforming into a bio-industry hub, driven by Boditech Med, a global company that exports in vitro diagnostic technology to approximately 140 countries.
Boditech Med has expanded its global reach to approximately 140 countries using Point-of-Care Testing technology that provides results in 10 minutes from a single drop of blood. The Chuncheon-based specialist, which began antibody manufacturing in 1998, can now diagnose infectious diseases, cardiovascular issues, and various cancers.
Chuncheon, Gangwon, is transforming beyond its reputation as a city of Dakgalbi and Makguksu into a hub for the bio-industry. As a result of local government-led bio-industry cultivation, a global company has emerged that exports in vitro diagnostic technology to approximately 140 countries. This journey, reported by the Ministry of Trade, Industry and Energy, contains the technological prowess of Boditech Med, an in vitro diagnostic specialist rooted in Chuncheon, and the innovation of Point-of-Care Testing (POCT).
"Tests that took 1–2 weeks can now be finished in 10 minutes on-site"
The core competitiveness of Boditech Med lies in "speed" and "convenience." Previously, when blood was collected and requested to professional testing institutions, it took anywhere from one week to two weeks to receive results. However, the POCT equipment developed by Boditech Med can confirm results in approximately 10 minutes using just a single drop of blood.
Seong Min-ung, a deputy manager at the central research institute, explained the technology for Therapeutic Drug Monitoring (TDM) kits, stating, "Using small equipment, results can be confirmed immediately on-site." Through this technology, patients can quickly understand their disease status without waiting for results from professional institutions.
The scope of the equipment's application is broad. It is capable of diagnosing not only infectious diseases such as COVID-19 or influenza but also cardiovascular diseases, glycated hemoglobin, and prostate or colorectal cancer. In particular, the flagship product 'i-CHROMATWO' has the ability to test for multiple diseases simultaneously by combining various cartridges.
Precision diagnostic devices completed through automated processes
To increase product precision, advanced automation systems have been introduced into the manufacturing process. In the production line of the cartridge manufacturing division, the camera process plays a key role. Cameras precisely check all products according to set standards, and only products that pass these standards move on to the next process.
In the final assembly stage, the touch of professional personnel is added. The assembled equipment undergoes strict quality control (QC) processes before being exported overseas. A production manager met on-site expressed pride, saying, "I feel excitement knowing that the products I make go abroad and save lives."
Boditech Med entered its full growth trajectory starting with exports to China in 2006. Currently, it is solidifying its position in the global market by supplying products to 130–140 countries annually. This represents the growth of a company that started with antibody manufacturing in 1998 into a global diagnostic company in 25 years.
A bio-heart growing with the talent of Chuncheon
The background behind Boditech Med being able to continue its growth while maintaining its headquarters in Chuncheon rather than Seoul was close cooperation with the local community. Chuncheon showed a strong will to foster the bio-industry, and the company established a win-win model by attracting a large number of local talents.
A company official explained, "As Chuncheon's will to foster the bio-industry and the company's growth align, we are keeping our headquarters here and continuing to expand our foundation." In fact, on-site, the company is creating stable employment within the region by focusing on employee welfare, such as awarding gold to employees with 10 years of service.
Boditech Med plans to rapidly expand its business areas beyond the field of point-of-care testing into chemiluminescence, urine testing, and blood analysis. Their long-term vision is to create a world where anyone can check their health with a single drop of blood, even in environments without refrigeration facilities or large hospitals.
Source: original video (YouTube)
0Comments
Comments are currently disabled.